ReviewInternational journal of nanomedicine2026
Engineering Nanomaterial Platform for Inflammatory Bowel Disease: Three-Dimensional Integration of Delivery Mechanism, Therapeutic Drug Delivery and Intelligent Material Design.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with a complex etiology and a high recurrence rate. Conventional treatments face significant limitations in targeting, stability, and efficacy. Going beyond conventional reviews that focus on isolated mechanisms, this review offers a systematic integration of three engineering perspectives: how to deliver (targeting mechanisms), what to deliver (pathology-based therapeutic payloads), and what to use for delivery (smart material design). We highlight emerging nanoplatforms-including nanozymes, probiotic-based nano-delivery systems, and stimuli-responsive nano-delivery systems-that address oxidative stress and gut dysbiosis, two core pathologies of IBD. We also discuss novel approaches for delivering nanodrugs to target cells and advocate for the use of hybrid synthetic/natural materials to achieve a balance between efficacy and safety of nanomaterials. However, a critical gap that must be confronted is that the vast majority of existing studies remain confined to acute, chemically induced colitis models (typically 7-14 days), which poorly recapitulate the chronic, relapsing nature of human IBD. Systematic validation of long-term safety and efficacy including biodistribution, metabolic clearance, and chronic toxicity profiles over extended periods is urgently needed before any meaningful clinical translation can be contemplated. This recognition of the acute-to-chronic translation gap constitutes a central critical stance of this review. This is not merely a methodological concern but a fundamental barrier that pervades the entire field: the disconnect between acute model readouts and chronic disease outcomes has systematically inflated translational expectations while masking the true challenges of long-term efficacy, safety, and durability. Addressing this gap requires not only acknowledging its existence but also implementing concrete, standardized protocols for chronic model evaluation. Multidisciplinary collaboration is urgently needed to accelerate clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.